Hengehold Capital Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,037 shares of the company’s stock after purchasing an additional 599 shares during the period. Hengehold Capital Management LLC’s holdings in Johnson & Johnson were worth $2,090,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Newfound Research LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $28,000. Islay Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $42,000. FAI Wealth Management boosted its holdings in shares of Johnson & Johnson by 45.9% in the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after purchasing an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC boosted its holdings in shares of Johnson & Johnson by 160.0% in the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares during the last quarter. Finally, Crewe Advisors LLC raised its stake in shares of Johnson & Johnson by 909.1% in the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after acquiring an additional 300 shares during the period. 67.44% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have recently commented on JNJ. Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a research note on Friday. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. Finally, Cantor Fitzgerald lifted their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $164.93.
Shares of JNJ opened at $146.36 on Friday. The company’s 50 day moving average price is $145.51 and its 200 day moving average price is $146.57. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00. The company has a market capitalization of $385.30 billion, a PE ratio of 23.01, a PEG ratio of 3.04 and a beta of 0.69. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The company had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. During the same period in the previous year, the firm posted $2.12 earnings per share. The company’s revenue for the quarter was up 1.7% compared to the same quarter last year. On average, equities analysts forecast that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s payout ratio is 46.54%.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: What is a portfolio manager?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.